You are here

Novartis sees profit margin hike as it revamps drug portfolio

Friday, June 19, 2015 - 05:50

Novartis is in a strong position relative to its peers thanks to recent advances with new drugs, including a widely anticipated heart failure medicine and a recently launched psoriasis injection.


NOVARTIS AG said on Thursday it expects to increase its profit margin this year as it restructures its drug portfolio and cuts costs, as well as generate cash for a higher dividend and smaller, strategic acquisitions.

"While we continue to improve productivity and generate

Market voices on:

Pair your daily business read with the perfect cup of espresso.

Subscribe to The Business Times today to receive your very own Nespresso Inissia coffee machine worth $188.

Find out more at

Powered by GET.comGetCom